Reference SummaryYamamoto S, Carcinogenesis 1998 May;19(5):855-60

Title

Clonal analysis of urothelial carcinomas in C3H/HeN<-->BALB/c chimeric mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.

Authors

Yamamoto S; Tatematsu M; Yamamoto M; Fukami H; Fukushima S

Journal

Carcinogenesis

Volume

19

Issue

5

Year

1998

Pages

855-60

Abstract

The histological background for multifocal and metachronous development of urothelial carcinomas remains equivocal, although accumulated genetic evidence suggests monoclonal origin of multiple urothelial carcinomas. Clonal development of various preneoplastic and neoplastic urothelial lesions of C3H<-->BALB/c chimeric mice induced by N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) was immunohistochemically investigated using a C3H strain-specific antibody. All tumor masses induced in the mice treated with 0.05% BBN for 20 weeks were composed of neoplastic cells of a single parental type, which is indicative of monoclonal lesions. Three of 10 animals harbored two or more separate carcinomas of different clonal type, which is indicative of multicentric development applicable in this model. Using DNAs derived from urothelial carcinomas and tumor-adjacent urothelium of chimeric mice, polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis and direct sequencing were performed for p53 gene exons 5-7. p53 mutations were identified in four of 11 (36%) dysplasias and non-invasive carcinomas (carcinoma in situ and pTa tumor) and 13 of 22 (59%) invasive carcinomas. Only in a single case were identical p53 mutations found in separate urinary bladder carcinomas. In contrast to the random distribution of urothelial proliferating units in chimeric mice without chemical supplement, invasive carcinomas in BBN-treated mice were accompanied by widely-distributed preneoplastic and neoplastic lesions of the same clonality, which occasionally had frequent foci of microinvasion. This is indicative of lateral clonal expansion of the clones, which precedes the bulk of invasive carcinomas. Thus, two aspects of 'field change' of the urothelium became evident in this model: either independent transformation events or lateral clonal expansion might, respectively, result in multicentric and monoclonal carcinoma development in the urinary tract.

Links

J:47713 – MGI References
9635874 – National Library of Medicine/PubMed

Strain Notes

Strain Note
BALB/c Mice were NOT carriers of infectious MMTV.

Models

Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
C3H/HeN : BALB/c Renal pelvis carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Renal pelvis

0 - 50

C3H/HeN Renal pelvis carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Renal pelvis

50

BALB/c Renal pelvis carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Renal pelvis

12.5

C3H/HeN : BALB/c Renal pelvis carcinoma in situ
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Renal pelvis

29

C3H/HeN : BALB/c Renal pelvis dysplasia
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Renal pelvis

14

C3H/HeN : BALB/c Renal pelvis hyperplasia
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Renal pelvis

100

C3H/HeN : BALB/c Renal pelvis papilloma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Renal pelvis

0

C3H/HeN : BALB/c Renal pelvis squamous cell carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Renal pelvis

29

C3H/HeN : BALB/c Renal pelvis transitional cell carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Renal pelvis

57

C3H/HeN : BALB/c Ureter carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Ureter

0

C3H/HeN Ureter carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Ureter

0

BALB/c Ureter carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Ureter

0

C3H/HeN : BALB/c Urinary bladder carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Urinary bladder

0 - 100

C3H/HeN Urinary bladder carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Urinary bladder

90

BALB/c Urinary bladder carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Urinary bladder

100

C3H/HeN : BALB/c Urinary bladder carcinoma in situ
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Urinary bladder

43 - 67

C3H/HeN : BALB/c Urinary bladder dysplasia
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Urinary bladder

57 - 100

C3H/HeN : BALB/c Urinary bladder hyperplasia
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Urinary bladder

100

C3H/HeN : BALB/c Urinary bladder papilloma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Urinary bladder

0

C3H/HeN : BALB/c Urinary bladder squamous cell carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Urinary bladder

67 - 71

C3H/HeN : BALB/c Urinary bladder transitional cell carcinoma
  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)
Urinary bladder

71 - 100